GGrantIndex
← Leaderboards

Khandan Keyomarsi

University Of Tx Md Anderson Can Ctr

Google Scholar ↗PubMed ↗ORCID ↗
$13,000,468
Attributed
$15,196,437
Total exposure
8
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.4M · FY2005–25
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$15,196,437 · 8

By mechanism

R01$10,838,034 · 4
R25$2,141,079 · 1
T32$1,688,145 · 1
P50$414,081 · 1
R29$115,098 · 1

Top collaborators

Most similar at University Of Tx Md Anderson Can Ctr

Same institution · by research overlap

Others in their field

Top investigators on “Protein Isoforms”

Research focus

Protein IsoformsLeadTumorIn VivoProgramsPhenotypeRecurrenceTumorigenesisCell CycleMolecular WeightLengthMalignant Breast NeoplasmMediatingAffectInnovationBiological ModelsGenerationsErbb2 GeneDesignMouse ModelPathway InteractionsCessation Of LifeOverexpressionClinically Relevant

Grant awards (46)

Targeting STAT3 for the Treatment of CDK4/6 Inhibitor Resistant Advanced Estrogen Receptor Positive Breast Cancer Patients$428,160
R01 · FY2025 · CA · contact PI
Targeting STAT3 for the Treatment of CDK4/6 Inhibitor Resistant Advanced Estrogen Receptor Positive Breast Cancer Patients$563,903
R01 · FY2024 · CA · contact PI
UPWARDS Training Program (Underrepresented Minorities Working Towards Research Diversity in Science)$430,381
R25 · FY2024 · CA · contact PI
Targeting STAT3 for the Treatment of CDK4/6 Inhibitor Resistant Advanced Estrogen Receptor Positive Breast Cancer Patients$581,711
R01 · FY2023 · CA · contact PI
UPWARDS Training Program (Underrepresented Minorities Working Towards Research Diversity in Science)$430,381
R25 · FY2023 · CA · contact PI
Cytoplasmic cyclin E is an early event for progression to invasive breast cancer$386,160
R01 · FY2023 · CA · contact PI
UPWARDS Training Program (Underrepresented Minorities Working Towards Research Diversity in Science)$430,381
R25 · FY2022 · CA · contact PI
Cytoplasmic cyclin E is an early event for progression to invasive breast cancer$386,159
R01 · FY2022 · CA · contact PI
Targeting STAT3 for the Treatment of CDK4/6 Inhibitor Resistant Advanced Estrogen Receptor Positive Breast Cancer Patients$587,495
R01 · FY2021 · CA · contact PI
UPWARDS Training Program (Underrepresented Minorities Working Towards Research Diversity in Science)$430,381
R25 · FY2021 · CA · contact PI
Cytoplasmic cyclin E is an early event for progression to invasive breast cancer$394,040
R01 · FY2021 · CA · contact PI
UPWARDS Training Program (Underrepresented Minorities Working Towards Research Diversity in Science)$419,555
R25 · FY2020 · CA · contact PI
Cytoplasmic cyclin E is an early event for progression to invasive breast cancer$1
R01 · FY2020 · CA · contact PI
Cytoplasmic cyclin E is an early event for progression to invasive breast cancer$537,419
R01 · FY2019 · CA · contact PI
Cytoplasmic cyclin E is an early event for progression to invasive breast cancer$394,040
R01 · FY2018 · CA · contact PI
Cytoplasmic cyclin E is an early event for progression to invasive breast cancer$160,000
R01 · FY2018 · CA · contact PI
Targeting the cell cycle in triple negative breast cancer$431,770
R01 · FY2015 · CA · contact PI
Multidisciplinary Subspecialty Pathology Research Fellowship Program$379,750
T32 · FY2015 · CA
Proeolytic Processing of Cyclin E in Breast Cancer$286,517
R01 · FY2015 · CA · contact PI
Targeting the cell cycle in triple negative breast cancer$420,413
R01 · FY2014 · CA · contact PI
Multidisciplinary Subspecialty Pathology Research Fellowship Program$282,498
T32 · FY2014 · CA
Proeolytic Processing of Cyclin E in Breast Cancer$277,922
R01 · FY2014 · CA · contact PI
Targeting the cell cycle in triple negative breast cancer$472,977
R01 · FY2013 · CA · contact PI
Multidisciplinary Subspecialty Pathology Research Fellowship Program$373,261
T32 · FY2013 · CA
Proeolytic Processing of Cyclin E in Breast Cancer$269,327
R01 · FY2013 · CA · contact PI
Targeting the cell cycle in triple negative breast cancer$506,141
R01 · FY2012 · CA · contact PI
Multidisciplinary Subspecialty Pathology Research Fellowship Program$438,857
T32 · FY2012 · CA
Proeolytic Processing of Cyclin E in Breast Cancer$286,517
R01 · FY2012 · CA · contact PI
Targeting the cell cycle in triple negative breast cancer$509,176
R01 · FY2011 · CA · contact PI
Proeolytic Processing of Cyclin E in Breast Cancer$286,517
R01 · FY2011 · CA · contact PI
Multidisciplinary Subspecialty Pathology Research Fellowship Program$213,779
T32 · FY2011 · CA
Proteolytic processing of cyclin E in breast cancer$36,150
R01 · FY2010 · CA · contact PI
Proteolytic processing of cyclin E in breast cancer$272,010
R01 · FY2009 · CA · contact PI
Cyclin E as a Novel and Powerful Prognosticator for Breat Cancer$247,477
P50 · FY2009 · CA · contact PI
Proteolytic processing of cyclin E in breast cancer$272,010
R01 · FY2008 · CA · contact PI
Cyclin E as a Novel and Powerful Prognosticator for Breat Cancer$166,604
P50 · FY2008 · CA · contact PI
Proteolytic processing of cyclin E in breast cancer$86,240
R01 · FY2008 · CA · contact PI
Proteolytic processing of cyclin E in breast cancer$272,010
R01 · FY2007 · CA · contact PI
Proteolytic processing of cyclin E in breast cancer$86,240
R01 · FY2007 · CA · contact PI
Proteolytic processing of cyclin E in breast cancer$280,134
R01 · FY2006 · CA · contact PI
Proteolytic processing of cyclin E in breast cancer$286,875
R01 · FY2005 · CA
Proteolytic Processing of Cyclin E in Breast Cancer$270,000
R01 · FY2004 · CA
Proteolytic Processing of Cyclin E in Breast Cancer$270,000
R01 · FY2003 · CA
Proteolytic Processing of Cyclin E in Breast Cancer$270,000
R01 · FY2002 · CA
Proteolytic Processing of Cyclin E in Breast Cancer$270,000
R01 · FY2001 · CA
THERAPEUTIC IMPLICATIONS AND MECHANISMS OF CYCLIN E$115,098
R29 · FY2000 · CA